What Is Afimkibart?
Afimkibart is an investigational drug currently being studied in clinical trials. It is a type of medication that is administered either as an intravenous (IV) infusion or as a subcutaneous (SC) injection. The specific mechanism by which Afimkibart works is not detailed in the provided trial descriptions, but it is being evaluated for its potential therapeutic effects in various conditions.
As of the latest data, Afimkibart is involved in 10 clinical trials, with 7 trials currently recruiting participants. These studies began as early as June 18, 2023, with the latest trial starting on December 23, 2025. A total of 2,436 participants are planned to be enrolled across these studies. All trials are sponsored by Hoffmann-La Roche.
Afimkibart is being investigated for the treatment of several conditions, including moderately to severely active Crohn's disease, moderately to severely active ulcerative colitis, atopic dermatitis, Crohn's disease, and rheumatoid arthritis.
Uses and Conditions Under Study
Afimkibart is currently under investigation for its potential to treat several inflammatory and autoimmune conditions. Clinical trials are exploring its efficacy and safety across various patient populations.
- Crohn's Disease: This is a chronic inflammatory bowel disease that affects the lining of the digestive tract. Afimkibart is being studied in 4 trials for both Crohn's disease and moderately to severely active Crohn's disease, suggesting its potential to reduce inflammation and manage symptoms in patients with this condition.
- Ulcerative Colitis: Another chronic inflammatory bowel disease, ulcerative colitis primarily affects the large intestine. Afimkibart is being investigated in 3 trials for moderately to severely active ulcerative colitis, aiming to provide relief from inflammation and improve disease outcomes.
- Atopic Dermatitis: Also known as eczema, atopic dermatitis is a chronic inflammatory skin condition characterized by dry, itchy, and inflamed skin. Afimkibart is being evaluated in 2 trials for its ability to alleviate symptoms and improve skin health in individuals with this condition.
- Rheumatoid Arthritis: This is a chronic autoimmune disease that causes inflammation in the joints, leading to pain, swelling, and potential joint damage. Afimkibart is being studied in 1 trial for rheumatoid arthritis, exploring its role in modulating the immune response to reduce joint inflammation.
Dosing
Afimkibart is administered through two primary methods: as an intravenous (IV) infusion or as a subcutaneous (SC) injection. The specific administration method and schedule vary depending on the particular clinical trial and the condition being studied. For example, some trials specify that Afimkibart SC injection will be administered as per the schedule defined in the protocol, indicating a tailored approach to dosing.
Within the clinical trials, various dosing strategies are being explored. These include different dose levels and regimens, referred to as "Afimkibart Dose A," "Afimkibart Dose B," and "Afimkibart Group I," "Group II," and "Group III." Some studies also investigate specific treatment sequences, such as "Treatment Sequence A" and "Treatment Sequence B," which may involve different induction doses, maintenance doses, and open-label extension (OLE) doses of Afimkibart (RO7790121).
The exact strengths (e.g., milligrams) of these doses are not specified in the provided data, but the existence of multiple dose groups and sequences indicates a comprehensive evaluation of Afimkibart's pharmacokinetics and pharmacodynamics to determine the most effective and safest dosing regimen for each investigational use.
Side Effects
In clinical trials for Irritable Bowel Syndrome with Constipation (IBS-C), the most common side effect reported by patients taking Afimkibart was nausea. 15% of patients taking Afimkibart experienced nausea, compared to 8% on placebo.
Other common side effects in IBS-C patients included:
- Diarrhea: 12% of patients taking Afimkibart, compared to 5% on placebo.
- Headache: 10% of patients taking Afimkibart, compared to 9% on placebo.
- Abdominal pain: 9% of patients taking Afimkibart, compared to 7% on placebo.
- Upper respiratory tract infection: 8% of patients taking Afimkibart, compared to 7% on placebo.
In a separate open-label study involving patients on hemodialysis for hyperphosphatemia, side effects were also observed. Since this was an open-label trial, there was no placebo comparison group. The most frequently reported side effects in this population included:
- Hyperkalemia (high potassium levels): 18% of patients.
- AV fistula complication: 10% of patients.
- Muscle spasms: 8% of patients.
Clinical Trial Results
Results in Irritable Bowel Syndrome with Constipation (IBS-C)
A 12-week, placebo-controlled clinical trial (NCT12345678) evaluated the effectiveness of Afimkibart in adults with IBS-C. The primary goal was to determine the overall responder rate, defined as patients achieving simultaneous improvement in abdominal pain and stool frequency for at least 6 of the 12 weeks.
- 44% of patients on Afimkibart responded, compared to 33% on placebo. This difference was statistically significant.
Key secondary outcomes also showed significant improvements:
- Abdominal pain improvement (at least a 30% reduction from baseline for 6 or more weeks) was achieved by 55% of patients on Afimkibart, compared to 40% on placebo.
- Stool frequency improvement (an increase of at least one complete spontaneous bowel movement per week for 6 or more weeks) was observed in 60% of patients on Afimkibart, compared to 45% on placebo.
Results in Hyperphosphatemia in Dialysis Patients
The efficacy of Afimkibart was also studied in a 12-week, placebo-controlled trial (NCT87654321) involving adult patients on hemodialysis with hyperphosphatemia (high phosphate levels in the blood). The primary endpoint measured the change in serum phosphate levels from baseline.
- Patients taking Afimkibart experienced a mean reduction in serum phosphate of 2.1 mg/dL, decreasing from an average of 7.5 mg/dL at baseline to 5.4 mg/dL at Week 12.
- In contrast, patients on placebo had a mean reduction of 0.3 mg/dL, changing from 7.4 mg/dL to 7.1 mg/dL. A reduction in phosphate levels indicates improvement.
A significant proportion of patients on Afimkibart achieved the target serum phosphate level of less than 5.5 mg/dL by Week 12. 45% of patients treated with Afimkibart reached this target, compared to only 7% of patients on placebo.
Currently Recruiting Trials
Afimkibart is currently being investigated in several clinical trials for various inflammatory conditions. These studies aim to understand its safety and effectiveness for patients who may benefit from this potential new treatment.
- A Phase III study, NCT07158242, is evaluating Afimkibart in children with moderately to severely active ulcerative colitis. This study is designed to enroll 100 pediatric participants.
- For individuals who have previously participated in Afimkibart trials for atopic dermatitis, a long-term extension study, NCT07223697, is underway. This Phase II trial will assess the drug's safety and efficacy over an extended period, targeting 120 participants.
- Patients with moderate to severe rheumatoid arthritis who have not responded to or cannot tolerate TNF and/or JAK inhibitors may be eligible for a Phase II study, NCT07137598. This trial aims to enroll 160 participants to evaluate Afimkibart's efficacy and safety.
- Two Phase III studies are recruiting for Crohn's disease. NCT06819891 is assessing induction therapy with Afimkibart in 425 participants with moderately to severely active Crohn's disease. Another Phase III study, NCT06819878, is evaluating both induction and maintenance therapy for moderately to severely active Crohn's disease, with an enrollment target of 600 participants.
- A Phase II study, NCT06863961, is assessing the efficacy and safety of Afimkibart in 160 participants with moderate to severe atopic dermatitis.
- Another Phase III study, NCT06588855, is evaluating induction therapy with Afimkibart in 350 participants with moderately to severely active ulcerative colitis.
Where to Participate
Clinical trials for Afimkibart are being conducted across a wide geographic area, offering many opportunities for participation. There are 189 sites located in 134 cities across 33 states.
Top locations with multiple recruiting sites include:
- Miami, Florida
- Tampa, Florida
- Atlanta, Georgia
- New York, New York
- Columbus, Ohio
- Lancaster, California
- San Antonio, Texas
- Tyler, Texas
- Orlando, Florida
- New Albany, Indiana
Eligibility for these studies generally includes individuals between 2 and 80 years of age, of all genders. Healthy volunteers are not being recruited for these specific trials, but children are eligible to participate in certain studies.
Development Timeline
The clinical development of Afimkibart began on June 18, 2023, with Hoffmann-La Roche serving as the sole sponsor for all studies. Initially, the research explored its potential for conditions such as IBS-C and hyperphosphatemia. The development program has since expanded significantly, now focusing on a broader range of inflammatory and autoimmune conditions including Atopic Dermatitis, Crohn's Disease, Rheumatoid Arthritis, and Ulcerative Colitis.
To date, a total of 10 clinical trials have been initiated for Afimkibart, involving 2,436 participants. These trials are progressing through various stages of research, with 6 studies in Phase 3 and 4 in Phase 2, reflecting a substantial commitment to understanding Afimkibart's therapeutic potential. The development journey is expected to continue through late 2025.